A37. ILD THERAPY I

Does HRCT Pattern Influence the Effect of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases?

Pub Date : 2020-05-01 DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1507 K. Brown, S. Walsh, A. Devaraj, Jin Woo Song, W. Wuyts, C. Valenzuela, R. Goeldner, S. Stowasser, R. Schlenker‐Herceg, A. Wells

Effect of Nintedanib in Patients with Limited and Extensive Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Data from the SENSCIS Trial

Pub Date : 2020-05-01 DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1525 N. Goh, C. Denton, D. Lynch, T. Maher, V. Smith, A. Prasse, V. Cottin, R. Spiera, C. Stock, M. Gahlemann, M. Alves, A. Wells

A Multicenter Retrospective Observational Study on Polish Experience of Pirfenidone Therapy in Patients with Idiopathic Pulmonary Fibrosis: A Preliminary Report of PolExPIR Study

Pub Date : 2020-05-01 DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1513 S. Majewski, A. Białas, Paweł Gomółka, K. Górska, E. Jassem, A. Kania, R. Krenke, J. Kuś, K. Lewandowska, M. Martusewicz-Boros, K. Roszkowski-Sliz, A. Siemińska, K. Sładek, M. Sobiecka, M. Tomczak, W. Tomkowski, E. Wiatr, B. Żołnowska, W. Piotrowski